This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale. Active years: 2026.
Company Filing History:
1 out of 39 
1 out of 123 
1 out of 12 Years Active: 2026
Title: Pierre Saintigny: Innovator in Cancer Prognosis
Introduction
Pierre Saintigny is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer research, particularly in the area of prognosis methods. His innovative approach aims to improve patient outcomes and treatment resistance assessments.
Latest Patents
Pierre Saintigny holds a patent for a prognosis method of cancer. This method involves determining the amount of the product of each of at least 21 genes from a group of 160 genes, as set forth in SEQ ID NO: 1 to SEQ ID NO: 160. This groundbreaking technique is designed to assess the prognosis of patient outcomes and their resistance to chemotherapy treatments.
Career Highlights
Throughout his career, Pierre has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and the Centre Léon Bérard. His work in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Pierre has collaborated with notable colleagues, including Véronique Maguer-Satta and Boris Guyot. These partnerships have enriched his research and fostered innovation in cancer prognosis methodologies.
Conclusion
Pierre Saintigny is a distinguished inventor whose work in cancer prognosis has the potential to transform patient care. His innovative methods and collaborations highlight the importance of research in improving treatment outcomes.